FDA Fast-Tracks Good Trip With Approved Psychedelic Drugs For Depression
Black Enterprise
Last updated: April 28, 2026
The U.S. Food and Drug Administration (FDA) has initiated a review process for three experimental psychedelic drugs aimed at treating depression. This development signifies a potential shift in mental health treatment, with the FDA offering priority review vouchers to the companies developing these novel therapies.
- The FDA's decision to review these psychedelic drugs for depression marks a significant step forward in exploring alternative mental health treatments. Three unnamed companies have received priority review vouchers, which can expedite the FDA's assessment of new drug applications and potentially lead to faster market access. This initiative reflects a growing interest in the therapeutic potential of psychedelics, substances previously associated with recreational use, for addressing complex mental health conditions like treatment-resistant depression. The review process will rigorously evaluate the safety and efficacy of these experimental drugs. The FDA's engagement suggests a move towards incorporating these compounds into mainstream medical practice, contingent upon successful clinical trials and stringent regulatory approval. This could open new avenues for patients who have not responded to conventional antidepressant therapies.
